Floyd Landis blasted the U.S. Anti-Doping Agency (USADA) on Friday regarding the agency’s efforts to subject cleared doping samples from last Tour de France to additional testing.

Landis tested positive for an elevated testosterone/epitestosterone ratio after winning stage 17 of the Tour last July but has challenged the handling of the sample and testing conditions at the French national anti-doping laboratory (LNDD) at Châtenay-Malabry, which processed the dope test.

In a statement issued Friday, Landis said he was responding to a report in the French sports newspaper l'Equipe regarding attempts by USADA to subject remaining B samples from the Tour de France to a more rigorous Carbon Isotope Ratio (CIR) test, used to distinguish natural from synthetic testosterone.

Landis said he was upset at the notion of testing samples he considers tainted at a lab whose procedures he is challenging in an appeal of his doping positive to USADA. That hearing is set for May 14.

"They got it wrong the first time and they're trying to get it wrong again," Landis said in the statement. “I am very concerned regarding the LNDD's handling of my samples over the last six months as well as the Anti-Doping Agencies' complete and consistent disregard of their own rules and procedures.

"With the steady stream of news flow regarding serious problems at the LNDD, it's impossible to understand USADA's motivation for this move unless it's simply another way to drain my resources in this fight to clear my name.

"My message to USADA and the LNDD is this testing should have been done right the first time."

Each of the samples requested by USADA turned in a testosterone/epitestosterone ratio of less than 4-to-1, so they did not constitute a positive and trigger further testing of the B samples. The sample that came from the 17th stage of the Tour, however, produced an 11-to-1 ratio, which triggered a counter-analysis of the B sample. Furthermore, that urine was also subject to the CIR test, which, in the case of the stage 17 sample, showed signs that some of testosterone in Landis’s body came from external sources. Landis argues his stage 17 positive came from a contaminated sample that LNDD continued to process in violation of World Anti-Doping Agency protocols.

"I have not taken testosterone or any other performance enhancing substance," Landis said.

Landis has agreed not to race in France this season, giving him no chance to defend the crown that could be stripped from him if the positive dope test stands.

"I'm 100-percent confident that if best practice in process and technology were applied to testing my sample back in July, I would be racing my bike this season," Landis said. Landis argued the additional tests would violate WADA and UCI rules.

"USADA's request for further analysis of ‘B’ samples is in clear violation the World Anti-Doping Code and UCI rules and is unprecedented in athlete anti-doping cases," the statement said. "USADA's illegal initiative would also cause the Landis team to expend unnecessary resources to halt a clearly prohibited activity - resources that have already been unduly and unfairly stretched by the ADA's unethical approach to their pursuit of unsubstantiated allegations against Landis."

Landis' legal team claims to have been denied full access to details of his results "and has no reason to believe that it would be provided with the results of any further tests", the statement said.

Landis attorney Maurice Suh expects it would not receive documentation from any additional testing.

"Illegal re-testing of these cleared samples is designed to further injure Floyd by costing him and his team substantial time and money, more deeply invading his privacy and destroying evidence that may later on be valuable in his defense," Suh said. "USADA continues to dramatically demonstrate that they have no interest in providing Floyd with a fair and just outcome to this process."